icotrokinra

News

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

J&J says 2026 sales could top $100 billion

J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

J&J shows its confidence in oral IL-23 drug for psoriasis

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.

News

J&J plots filings after psoriasis drug clears phase 3 test

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

News

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable ef

J&J gets FDA okay for psoriasis drug icotrokinra

J&J says 2026 sales could top $100 billion

11 high-impact drugs to look out for in 2026

J&J shows its confidence in oral IL-23 drug for psoriasis

J&J plots filings after psoriasis drug clears phase 3 test

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

AbbVie tries a new approach in 340B programme battle

Using AI-driven synthetic personas to take your insights fur...

icotrokinra

Editor's Picks